Alireza Rezania, PhD

Scientist, executive and regenerative medicine trailblazer

Dr. Alireza Rezania joined Satellite Bio in September of 2023 as Chief Scientific Officer. is a tenured scientist and leader, with more than 20 years of cell therapy discovery and development expertise.

Rezania has successfully guided multiple regenerative medicine products from their early discovery stages through early clinical development in various therapeutic areas, including wound healing, cartilage repair, immune therapies and Type 1 diabetes.

Prior to Satellite, Rezania was Head of Regenerative Medicine at CRISPR Therapeutics, where he was responsible for the development and advancement of the first immune-evasive cell therapy product candidate for the treatment of Type 1 diabetes into clinical development. Prior to CRISPR, he held multiple senior scientific roles, including at ViaCyte, a cell therapy company acquired by Vertex, and increasing responsibilities across Johnson & Johnson companies. Among his noteworthy achievements are the development of a scalable process for generating therapeutic cells derived from stem cells, the creation of next-generation immune isolation devices, and the submission of numerous regulatory filings for combination cell-based products, including gene-edited cells.

With over two decades of industrial experience, Rezania has skillfully managed relationships with a diverse array of industrial and academic partners, resulting in the publication of over two dozen journal articles and the issuance of more than 60 patents.

He earned his PhD in Biomedical Engineering from Northwestern University, a Master's degree in Biomedical Engineering from Rensselaer, and a Bachelor's degree from Washington University.